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Abstract
Identification of gene expression changes that improve prediction of survival time across all glioma grades would be
clinically useful. Four Affymetrix GeneChip datasets from the literature, containing data from 771 glioma samples
representing all WHO grades and eight normal brain samples, were used in an ANOVA model to screen for transcript
changes that correlated with grade. Observations were confirmed and extended using qPCR assays on RNA derived from 38
additional glioma samples and eight normal samples for which survival data were available. RNA levels of eight major
mitotic spindle assembly checkpoint (SAC) genes (BUB1, BUB1B, BUB3, CENPE, MAD1L1, MAD2L1, CDC20, TTK) significantly
correlated with glioma grade and six also significantly correlated with survival time. In particular, the level of BUB1B
expression was highly correlated with survival time (p,0.0001), and significantly outperformed all other measured
parameters, including two standards; WHO grade and MIB-1 (Ki-67) labeling index. Measurement of the expression levels of
a small set of SAC genes may complement histological grade and other clinical parameters for predicting survival time.
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Introduction
Glioma tumors are the most common of central nervous system
(CNS) neoplasms. The median survival times for low grade (stage
I–II) patients average 6–8 years [1,2] but are only about 3 and 1
year for patients with anaplastic astrocytoma (WHO grade III) and
glioblastoma (WHO grade IV), respectively [3,4,5].
In a widely used measure, the level of Ki-67 protein is
determined using an antibody called MIB-1 in a labeling index
(MIB Li) that correlates with aggression and survival time in
gliomas [6,7,8,9,10] and many other cancers [11,12,13,14,15,16].
Furthermore, one report indicated that RNA expression of Ki-67
correlated with survival time better than the antibody test, MIB Li,
in colorectal carcinoma [17].
In this study, we looked at glioma grades II, III, and IV to
uncover additional genes whose RNA expression correlated with
grade and survival time. First, we used the statistical analysis suite
WebArrayDB (http://www.WebArrayDB.org) [18] to analyze
available microarray datasets of glioma RNA expression from
various platforms that had already been used to identify hundreds
of significant correlations of RNA levels with increasing glioma
grade [19,20,21], including data stored at the Cancer Genome
Anatomy Project (http://cgap.nci.nih.gov/Genes).
We found eight genes involved in the mitotic spindle assembly
checkpoint (SAC) which were positively and reliably correlated
with grade. SAC proteins are used in chromosome segregation
during mitosis [22,23,24]. These genes were of interest because an
increase in their expression likely implied increased cell division, a
phenotype with the potential to correlate with survival in almost
any glioma. Crucially, a few of these genes outperformed the
current standard for proliferation measurement, Ki-67 (a gene
expressed at the same time in the cell cycle [25,26,27,28]),
measured either using MIB-1 antibody as a labeling index (MIB
Li) or measured at the RNA expression level. Furthermore, these
genes had not previously been studied for their behavior in glioma.
We used 38 additional glioma samples to further evaluate the
association of transcript levels of eight SAC genes with glioma
grade and patient survival time.
Materials and Methods
Patient samples
Forty four samples, including 38 human glioma specimens (12
for grade II, 13 for grade III, 13 for grade IV) and 6 control
samples, were collected from 2003 to 2005 by the Department of
Neurosurgery, 1st Affiliated Hospital of Jilin University, China.
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had received no therapy before sample collection. Samples were
collected immediately after surgical resection, snap frozen, and
stored at 280uC. Survival time was defined as the period from the
date of surgery to the date of death. All surviving patients were
followed up for at least five years. All histological diagnoses were
made on formalin fixed, paraffin-embedded H&E sections and Ki-
67 immunostain, and were categorized according to the 2007
WHO classification, again [29]. Six control samples (normal brain)
were obtained from patients undergoing surgery for brain trauma
(n=4) and epilepsy (n=2). They were reviewed to verify the
absence of tumor.
Ethics statement
Informed written consent was obtained from all patients after an
explanation of the study. Samples were collected only when
necessary as part of treatment. Only samples in excess of what was
needed for pathological assessment were used for research. All
samples were coded and handled anonymously. Use of patient
material was approved by the Institutional Review Board of Jilin
University.
Cell proliferation evaluated using MIB Li and Mitotic
Index
Slides cut from each glioma used in the study were evaluated by
two experienced pathologists independently using direct light
microscopy. The measurement of Ki-67using the MIB Labeling
index (MIB Li) [30] was calculated by determining the percentage
of neoplastic cells that were immunopositive. More than 1000 cells
were counted in ten separate fields at 4006magnification for each
specimen. Only strong nuclear stain was regarded as positive, and
weak nuclear or cytoplasmic stain was regarded as negative. The
mitotic index (MI) was counted in HE stained slides using scores
from 0 to 3, 0: no mitotic figures; 1: #2 mitotic figures/field; 2: (3–
4) mitotic figures/field; 3: $5 mitotic figures/field [6].
RNA isolation and quality evaluation
Total RNA was isolated using TRIzol Reagent (Invitrogen,
CA), following the manufacturer’s instructions. The concentration
and purity of isolated RNAs were assessed by absorbance (A)
readings on a UV spectrophotometer (Hitachi) at 260 and
280 nm, and electrophoresis on a Bio-Rad Experion automated
electrophoresis system(Bio-Rad Laboratories, Hercules, CA). The
mean ratio value of A260/280 for all RNA samples was
1.80(60.10); the 28S/18S ratio of samples$1.5, and no evidence
of ribosomal peak degradation was observed.
Real-time quantitative reverse transcription PCR
Exactly 500 ng total RNA from each sample was used to
generate cDNA using SuperScript II Reverse Transcriptase
(Invitrogen, Carlsbad, CA). Pairs of PCR primers of 18 to 25 bp
in length were designed using AlleleID Version 7.0 software
(Premierbiosoft, Palo Alto, CA, Information S1). Real-time
quantitative PCR (qPCR) was then carried out using an ABI Prism
7900 Sequence Detection System (Applied Biosystems, Carlsbad,
CA). A quantity of 15 ng of cDNA was used in a 25 ml PCR
reaction containing the appropriate primers and 16SYBR Green
PCR Super mix (BioPioneer, San Diego, CA). Parallel experi-
ments were done using an 18S and HPRT1 primer set [31]. Each
sample was run in triplicate, and each PCR experiment included
one no-template negative control. The Pfaffl [32] method was used
to determine the relative ratio of gene expression for each gene,
corrected using expression of two controls by incorporating a
normalization factor=(quant[18S]*quant[HPRT1])
1/2, and refer-
enced to non-neoplasic brain tissues. All primer pairs used in this
study had.90% amplification efficiency (Information S1).
Statistical analysis of qPCR data
The qPCR CT values were used to calculate the fold changes of
RNA abundance for SAC genes normalized to the reference genes
(18S+HPRT1). Before fitting to regression models, the adjusted
fold change values for each gene were standardized by subtracting
the mean of all values obtained from all samples for each gene and
then divided by their standard deviation.
Differential analysis
For each gene, the differences in expression levels across
different WHO grades were tested using one-way ANOVA, and
further pair-wise comparisons were made through a simultaneous
interface using general parametric models [33].
Relationship of SAC genes and WHO grades
Linear models were used to explore the relationship between
SAC genes and WHO grade. The WHO grades were mapped to
numbers using 1 for grade II, 2 for grade III, and 3 for grade IV.
These numbers for grades were log-transformed before fitting to
the models. Models were fitted to data using leave-one-out cross-
validation, i.e., to predict the grade for each of the 38 samples,
models were trained with data from the other 37samples. All
possible combinations of the eight SAC genes were tested to obtain
the models with the most accurate predictions of WHO grade.
Cox regression analysis
Cox proportional hazards regression was used to model the
relationship between survival and all available parameters,
including age, sex, WHO grade, tumor diameter, and the level
of mitotic checkpoint gene mRNA expression. The optimized
model was established from all possible combinations of all
variables and factors according to the Akaike information criterion
(AIC) [34]. Cox regression was performed using the survival
package for the R software environment. Overall survival curves
(from diagnosis to death) were obtained using the Kaplan-Meier
method. In each survival curve, maximally selected log-rank
statistics [35] was used to determine the cutoff-point, an expression
value which separates the low-expression samples from the high-
expression samples. A p value of less than 0.05 was considered
statistically significant.
Prediction of survival time based on SAC genes
34 samples of known survival time (in months) were used to
build the linear model for prediction of survival time by SAC
genes. Four samples were excluded due to having a last doctor visit
but not an exact date of death. The model that best fit the data was
selected from all possible combinations using least squares
estimates (LSE).
Results
Genes chosen for qPCR assays
In order to select genes of potential interest, four independent
microarray datasets [19,20,36,37] were used (Table 1). These
datasets consisted, in total, of 8normal control, 29 grade II, 116
grade III and 618 grade IV gliomas.
Data were analyzed on the WebArrayDB cross-platform
analysis suite [18] using an ANCOVA model. Genes were sorted
in ascending order according to the p values for WHO grade, after
Checkpoint Gene Expression Predicts Survival Time
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genes that correlated most significantly with grade were clustered
using DAVID [38,39] and KEGG [39]. Among these most highly
ranked genes were at least 25genes associated with cell cycle; for
example, TGFb, MDM2, Smc3, p300, PTTG, HDAC, Cdc6,
Cdc14, CDC25A, GADD45, Kip1,2, ORCs, ATMATR, CDK2,
CycA, CycB, CycD, MCMs, Wee1, and including four genes that
are specifically related to mitotic spindle assembly; BUB1, BUB1B,
CDC20, and TTK. Other highly ranked genes included RRM2,
FOXM1, p53, and TOP2A. This observation was expected
because cancer is a proliferative disease. Expression of these genes
is of particular practical interest as markers of progression because
it may be altered in most tumors, regardless of the causative
mutations. Such markers might be quite reliable for staging tumors
despite otherwise massive tumor heterogeneity.
The SAC pathway had not been investigated previously for
biomarkers of progression in glioma. Thus, we focused our
attention on the SAC genes in this study. We added four
additional genes, CENPE, BUB3, MAD1L1 and MAD2L1, which
are part of the SAC pathway and highly correlated with glioma
grade but were not among the 2000 top genes correlating with
grade identified in the microarray survey (Table 2).
RNA expression of SAC genes increases with grade
The expression levels of eight SAC genes were examined in 38
human glioma samples and 6 normal brain tissues by qPCR
(Information S2 and S3). The 44 samples were classified into
four groups: normal, grade II, grade III, and grade IV glioma. For
each of the selected genes, the differences in expression levels
across the four groups were evaluated using ANOVA. The
significance was adjusted for the false discovery (Table 3). Not all
pairs in this table are significant because the distance between
sample classes is different. Normal and grade IV have a large
biological difference, and we can see very significant changes for
many genes, whereas the difference between normal and grade II
is subtle and we find only two genes that rise to the highest level of
significance.
Overall, expression of the eight SAC genes showed a significant
increase with increasing WHO grades (Table 3). In contrast to
normal samples, overexpression is observed for all genes in grade
IV and for most genes, except CENPE, MAD1L1 and MAD2L1,
in grade III (p,0.05). BUB1 and TTK overexpression in grade II
reached statistical significance (p,0.05). Further research may
indicate if these two genes have potential utility in classifying early
stage tumors.
In pairwise comparisons of glioma samples, two genes (BUB1B,
CDC20) showed significant difference between grade II and grade
IV (p,0.05), while expression in grade III does not significantly
differ from grade II or grade IV for most genes. This might be
explained by the small sample size. The only two exceptions are
CDC20 and BUB1B, which changed significantly between all
Table 1. Independent glioma RNA expression microarray
datasets.
# of cases Sample Type GEO ID
Affymetrix
Platform
85 Tumor tissue
(frozen)
GSE4412 HG-U133A
265 & 7 controls Tumor tissue
(frozen)
GSE16011 HG-U133Plus2.0
15 & 1 control Tumor tissue
(frozen)
GSE19728 HG-U133Plus2.0
398 Tumor tissue
(frozen)
TCGA_GBM HT_HG-U133A
doi:10.1371/journal.pone.0025631.t001
Table 2. Correlation of SAC gene expression with glioma grade using four independent Affymetrix GeneChip datasets.
Gene symbol synonyms
Sequence
Accession ID
Affymetrix
Probe Set ID
Gene rank. 22277
probe sets p value* Description
BUB1 BUB1A/BUB1L/hBUB1 NM_004336 209642_at 1146 1.07E-26 BUB1 budding uninhibited
by benzimidazoles 1
homolog
BUB1B BUBR1/hBUBR1/SSK1 NM_001211 203755_at 1629 2.05E-27 BUB1 budding uninhibited
by benzimidazoles 1
homolog beta
BUB3 BUB3L/hBUB3 NM_004725 201456_s_at 6467 2.75E-09 BUB3 budding uninhibited
by benzimidazoles 3
homolog
CDC20 CDC20A/p55CDC NM_001255 205046_at 99 5.24E-27 Cell division cycle 20
homolog
CENPE KIF10 NM_001813 202870_s_at 3122 7.12E-44 Centromer protein E,
312 kDa
MAD1L1 MAD1/PIG9 NM_003550 204857_at 2469 1.68E-07 MAD1 mitotic arrest
deficient-like 1
MAD2L1 MAD2/HSMAD2 NM_002358 203362_s_at 8813 4.22E-19 MAD2 mitotic arrest
deficient-like 1
TTK MSP1/MPS1L1 NM_003318 204822_at 820 1.29E-26 TTK protein kinase
Ki-67 Mki67 NM_002417 212022_at 3820 1.28E-17 antigen identified by
monoclonal antibody Ki-
67
*p value calculated using ANCOVA.
doi:10.1371/journal.pone.0025631.t002
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size, random groups of only half of the patient samples were tested
and all statistically significant observations about the top three
genes were supported (data not shown).
We also measuredKi-67 RNA levels because the corresponding
protein is currently used to determine a labeling index for glioma
[6,7,8,9,10,11,12,13,14,15,16] and previous work indicated the
RNA might be a better prognosticator [17]. Interestingly, Ki-67
RNA level was outperformed by BUB1B and CDC20, overall, and
by BUB1 and TTK when applied to grade II gliomas (Table 3).
Identification of WHO grades by SAC genes
Expression of six SAC genes, BUB1, BUB1B, CDC20, CENPE,
MAD1L1 and TTK were found to be significantly positively
correlated with WHO grades of glioma patients (p,0.01,
Table 3). RNA expression levels of both CDC20 and BUB1B
had a Pearson’s correlation coefficient with grade of higher than
0.8. After screening all possible combinations of eight SAC genes,
we formulated a four-gene model with the highest accuracy in
identification of the WHO grades of gliomas (Information S4):
Grade~floor 0:5 ð
ze0:6130z0:1273 BUB1Bz0:2878 CDC20z0:0587 MAD1L1{0:0297 TTK ð1Þ
In which a value of 1 predicts grade II, 2 predicts grade III, and
3 or a greater value predicts grade IV. The values for BUB1B,
CDC20, MAD1 L1 and TTK are normalized expression ratios
(see Materials and Methods). BUB1B and CDC20 are the most
important factors in this model and they have a much bigger
weight than MAD2L1. Among the 38 patients used for regression,
34 (89.4%) are classified as expected by this model, and four
patients were classified to grades adjacent to observed grades.
Using leave-one-out cross-validation, 34 samples were classified in
the same grade as estimated by histological examinations by the
pathologists, giving 89.4% accuracy, and the other 4 predictions
were all adjacent to observed grades (Information S5).
CDC20wastheonlygeneincludedinallofthese35combinations
while the second most frequently occurring gene, BUB1B, was
found in 29 of these combinations. This highlights the possibly
useful role of CDC20 and BUB1B in estimating grades of glioma
samples.
Multivariate analysis of the correlation between
prognostic parameters and survival time
Cox multivariate proportional hazards models with different
combinations of factors were obtained for the 38 patient samples
where survival time was known (Table 4).
In the first model in Table 4, which excluded SAC gene
expression data, WHO grade were significantly correlated with
survival time, but age and sex were not. In models that included
SAC gene expression (model 2 and model 3) grades no longer
added information and only BUB1B was identified as a significant
factor with the highest risk ratio (p,0.01). Indeed, even Ki-67
protein as measured by the labeling index (MIB Li) and mitotic
index (MI), which significantly correlate with survival time
(Information S6), did not add additional information when
SAC genes were included (model 2). In model 3 each combination
of factors is examined to determine the minimum number of
factors that capture the most information about survival time.
Only factors that add any information to the prediction are
retained. BUB1B dominated this regression, with small adjust-
ments from CDC20 and from MIB Li. Thus, it appears that
BUB1B is an independent prognostic factor for survival time.
Prediction of survival time using SAC gene expression
By applying linear regression to all possible gene combinations,
we obtained a four-gene combination with the minimal least
squares estimate (LSE, 34.96) in leave-one-out cross-validation:
BUB1, BUB1B, CENPE, and TTK (Information S7). The
regression equation for these patients is:
Survival months ½  ~20:1184z2:4820   BUB1
{10:8036   BUB1B{3:0840   CENPEz1:6618   TTK
ð2Þ
The predicted months of survival closely matched the observed
values for most patients (Four-Gene Model in Figures 1, 2).
Coefficients used in cross-validation and prediction for each
sample is listed in Information S8. Among the four genes used in
this model, the coefficient for BUB1B was much higher than that
of the other genes, which consequently contributed little additional
information.
BUB1B is the only gene that appeared in all gene combinations
that can be used to make survival time predictions with the lowest
Table 3. Validation of the mitotic checkpoint genes in glioma tumors by qPCR.
Gene P (ANOVA) III/II IV/II IV/III II/normal III/normal IV/normal
Fold p Fold p Fold p Fold p Fold p Fold p
BUB1 1.35E-06 0.39 1.00E+00 1.01 3.76E-01 0.62 1.00E+00 3.13 5.46E-04 3.53 1.32E-05 4.14 8.31E-07
BUB1B 4.02E-10 1.30 1.18E-03 2.11 9.18E-08 0.81 1.27E-01 0.75 2.43E-01 2.05 1.22E-05 2.86 1.11E-09
BUB3 2.08E-02 0.46 1.00E+00 0.38 9.94E-01 0.08 1.00E+00 1.18 2.39E-01 1.64 2.89E-02 1.56 2.62E-02
CDC20 1.66E-13 1.41 4.58E-07 2.14 3.59E-13 0.73 4.97E-02 0.43 3.95E-01 1.84 9.73E-08 2.58 2.17E-12
CENPE 5.78E-04 0.22 1.00E+00 1.28 6.46E-02 1.06 2.57E-01 1.14 2.43E-01 1.36 6.16E-02 2.42 3.93E-04
MAD1L1 8.76E-03 0.12 1.00E+00 1.38 1.87E-01 1.26 3.29E-01 0.99 5.01E-01 1.10 3.39E-01 2.37 8.85E-03
MAD2L1 2.08E-02 0.44 1.00E+00 1.27 2.22E-01 0.83 1.00E+00 0.87 5.81E-01 1.31 2.16E-01 2.14 1.97E-02
TTK 4.80E-05 0.03 1.00E+00 0.38 9.94E-01 0.41 1.00E+00 2.13 1.07E-03 2.10 4.04E-04 2.51 6.66E-05
Ki-67 1.35E-06 1.07 1.05E-01 1.71 6.47E-04 0.64 8.49E-01 1.06 2.27E-01 2.12 3.92E-04 2.76 1.68E-06
p,0.05 are shown in bold. p values were adjusted with FDR.
doi:10.1371/journal.pone.0025631.t003
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Model Parameter Risk ratio 95% CI p
1. Cox regression without genes Sex (male vs female) 0.35 0.60–2.63 0.56
Age 0.53 0.98–1.04 0.47
WHO (Grade III vs Grade II) 1.08 0.19–1.03 0.59
WHO (Grade IV vs Grade II) 3.56 0.07–0.49 0.01*
2. Cox regression with genes Sex (male vs female) 0.57 0.19–1.72 0.32
Age 1.03 0.99–1.07 0.12
WHO (Grade III vs Grade II) 0.43 0.06–3.10 0.58
WHO (Grade IV vs Grade II) 0.19 0.01–2.79 0.23
BUB1 1.07 0.54–2.12 0.84
BUB1B 7.38 1.72–31.65 0.01*
BUB3 0.88 0.54–1.44 0.62
CDC20 0.60 0.15–2.32 0.46
CENPE 1.30 0.69–2.46 0.41
MAD1L1 0.73 0.32–1.64 0.44
MAD2L1 1.58 0.66–3.77 0.30
TTK 0.65 0.31–1.34 0.24
MIB Li (Ki-67 antibody) 1.08 0.98–1.21 0.13
MI 1.32 0.45–3.85 0.61
3. Optimized Cox regression BUB1B 10.98 2.87–17.10 1.90E-05*
CDC20 0.38 0.20–0.69 1.69E-03*
MIB Li (Ki-67 antibody) 1.57 1.02–1.14 4.72E-03*
Asterisk (*) for p,0.01, n=38.
doi:10.1371/journal.pone.0025631.t004
Figure 1. Observed versus predicted survival times using the four gene model.
doi:10.1371/journal.pone.0025631.g001
Checkpoint Gene Expression Predicts Survival Time
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e25631least square errors (LSE) (Information S9). Thus, we also fitted
BUB1B alone to a regression model:
Survival months ½  ~20:119811:2606   BUB1B ð3Þ
This single gene model obtains a LSE of 45.64 in cross-
validation, and the plots of predicted versus observed survival time
look very similar to the plots using the four-gene model in equation
(2) (Figure 2).
Kaplan-Meier survival curves for BUB1B and MIB Li
In the analysis presented in Figure 3, six charts are plotted
using grade II, grade III, and grade IV with separate curves for
low BUB1B levels, high BUB1B levels, low MIB Li and high MIB
Li. The cutoffs points within each grade are selected to maximize
discrimination in each set of data. If there were no correlation
between BUB1B expression or MIB Li and survival time then no
significant cutoff would be found. All BUB1B expression charts
display significantly different survival time between low expression
BUB1B samples and high expression BUB1B samples (p,0.01) in
three WHO grade. Thus, the expression level of BUB1B reveals
information on the survival probability for glioma patients beyond
that revealed by grade alone. In contrast, MIB Li showed little or
no significant difference for any grade and was outperformed by
BUB1B for all grades.
SAC protein levels increases with grade
The Human Protein Atlas (HPA, http://www.proteinatlas.org/)
collects information on proteins detected by antibodies in a wide
variety of tissue samples arranged as tissue microarrays, including
gliomas. The result of immunohistochemistry for antibodies
directed against seven of the SAC proteins in our study (all except
CENPE) are available for 11 grade III/IV glioma and three normal
brain cores in the HPA database. The level of staining by each
antibody was scored by board certified pathologists as: negative,
weak, moderate, or strong. Example images are shown in
Information S10. We translated the four different categories to
0, 1, 2, and 3 to permit analysis using a Wilcox rank sum test. The
demarcations of scoring categories are imprecise and subjective.
Nevertheless, antibody stains for proteinsBUB1, BUB1B, BUB3,
CDC20, and TTK were at significantly higher levels in high grade
glioma than in normal brain by this test (Table 5). This data is
consistent with the higher mRNA expression levels we observed in
both grade III and grade IV for these five genes compared to
normal brains. Antibody staining of two proteins, MAD1L1 and
MAD2L1, appeared to experience less increase with grade, which is
also consistent with our observation that for these two genes RNA
overexpression was significant relative to normaltissue only ingrade
IV and not in grade III (Table 3).
Discussion
WHO grade of gliomas is currently the major indicator used for
prognosis and for treatment protocols. The 2007 WHO grading
system [29] uses histopathological characteristics such as brisk
mitotic activity (Ki-67: MIB Li) [40], increased cellularity,
necrosis, and frequent invasion of brain parenchyma to classify
gliomas into four broad grades. Sophisticated methods of assessing
survival based on other clinical parameters have also been
developed [41].
In combination with the current clinical methods, gene
expression profiles are potentially powerful predictors of survival
[19,20,21] with additional potential as markers for diagnosis, as a
guide to therapy, and even as potential therapeutic targets.
Genetic analyses over the past several years have defined the
major targets that are associated with the formation of glioma
including EGRF, PTEN, TP53, IDH1/2, CDKN2A, MGMT,
and others [42], which likely have downstream effects on other
genes to improve tumor survival. For example, p53 inhibits tumor
cell growth through the indirect regulation of CDC20, one of the
genes of interest in this report [43]. While the lesions involved in
causing progression in glioma may vary from patient to patient,
these changes likely converge on a few critical regulatory
pathways. Any expression changes in these common pathways
Figure 2. Scatter plots of observed and predicted survival times using leave-one-out cross-validation on 34 deceased glioma
patients.
doi:10.1371/journal.pone.0025631.g002
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most tumors, regardless of the prime movers in disease progression
in any particular tumor.
We further investigated hundreds of microarray profiles of
glioma and a few normal brain tissues that had previously been
used successfully to predict survival time in gliomas [19,20,21].
Our goal was to identify a small subset of markers that could
reliably substitute for or improve uponKi-67 measurements using
MIB Li [6,7] or multigene expression profiles, and then to confirm
these markers on independent samples.
To identify pathways that might undergo changes in RNA
expression with increasing grade using the WebarrayDB cross-
platform analysis suite [18]. Among a number of different groups
of functionally related genes that correlated with grade, one group
contained genes associated with the spindle assembly checkpoint
(SAC). Importantly, if these genes were to be of potential clinical
utility, expression of at least two of these SAC genes appeared to
correlate better with grade than did Ki-67 RNA (Table 2). The
SAC is involved in accurate chromosome segregation between two
daughter cells during mitosis. There are already data in the
literature that suggest that SAC gene expression may be associated
with aggressiveness of cancers. Studies of malignant bladder
cancer and breast cancer suggested that increased mRNA levels of
mitotic checkpoint genes are correlated with tumor progression
[44,45]. A strong correlation between expression of BUB and
gastric cancer cell proliferation has been observed [46]. Combined
expression of BUB1B and PINK1 was the best predictor of overall
survival in adrenocortical tumors by microarray [47]. Many
immunohistochemistry investigations have shown that overexpres-
sion of BUBR1, the protein of BUB1B, significantly correlates with
higher histological grade, advanced pathological stage, and high
cell proliferation in different types of tumors, e.g. with tumor
recurrence and disease progression in bladder cancer [44]; with
deep invasion, lymph node metastasis, liver metastasis, and poor
prognosis in gastric cancer [48]; and with advanced stage, serous
histology and high grade in ovarian cancer [49]. On the other
hand, a lower level of BUBR1 correlated with low recurrence-free
survival rates in ovarian cancer [49] and aneuploidy in colorectal
cancer [50]. BUBR1 was used as an independent predictor for
poor prognosis in pancreatobiliary-type tumors by tissue micro-
array [51]. However, correlations of SAC gene expression with
aggressiveness have not been reported for glioma except for
CDC20 that has higher expression in glioblastoma than in low
grade glioma [52].
To validate the RNA expression changes in SAC genes in the
microarray data (Table 2), we performed qPCR analysis on RNA
from six additional normal brain samples and 38 additional
gliomas that had survival time data. The eight SAC genes were
significantly overexpressed at the RNA level in glioblastomas
(grade IV) in comparison to controls (Table 3), and all were
almost monotonically increased in expression along with grade,
indicating that they might serve as prognostic glioma markers.
Two genes, BUB1B and CDC20, outperformed Ki-67 RNA. This
is consistent with past reports for colorectal carcimona in
whichMIB-1 Li had no significant correlation with Ki-67 mRNA
expression [17,53]
Figure 3. Kaplan-Meier estimates of overall survival time. Panels A, B, and C use BUB1BRNA expression as determined by qPCR. Panels D, E,
and F use the MIB labeling index (MIB Li) that measures Ki-67 protein. Log-rank statistics is used to determine the cutoff-point, which is the expression
value that divides low-expression samples from high-expression samples. OS=Overall survival.
doi:10.1371/journal.pone.0025631.g003
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between low grade gliomas and normal brain tissues (p,0.01,
Table 3). Further research will indicate if these two genes have
utility in classifying early stage tumors. These genes have
previously been associated with cancer though not glioma;
BUB1 mutation was associated with lymph node metastasis and
shorter relapse-free survival after surgery in colorectal cancers
[54], TTK had an increased expression level in anaplastic thyroid
carcinoma [55], and TTK expression correlated with tumor node
metastasis (TNM) stage in gastric cancer [56].
We used gene expression of SAC genes to build models that
correlate with grade. A4-gene regression model (Equation 1) was
sufficient to generate 92.1% identity with grade. Considering the
potential bias in identification of grades by histological diagnoses
and the arbitrary boundaries between adjacent grades, this
performance is extremely good.
In a multivariate proportional hazards model without genes
(Model 1 in Table 4) WHO grade is identified as a significant
factor for survival (p,0.05). However, WHO grade adds no power
to classification when SAC gene expression profiles are added to
the model (Model 2 in Table 4). MIB labeling index and mitotic
index (MI) also add no additional information in model 2. WHO
grade is not present when this model is optimized to identify
factors that best predict outcome (Model 3 in Table 4). Although
MIB Li is retained in this model, it is a minor factor compared to
BUB1B expression. Thus, qPCR assays of SAC genes, particularly
BUB1B, might be used as an objective complement to histological
diagnosis for identification of glioma grades, MIB Li, MI, and the
multigene RNA profiles that have been proposed [19,20,21].
Figure 3 illustrates that BUB1B was able to distinguish among
grade IV samples with significance (p=0.003). Two previous
studies are used microarray data to subclassify glioblastomas
(grade IV) [57,58]. The SAC genes were not prominent among
these genes. However, given that our study encompassed all
grades, this lack of concordance is not surprising. We will need
larger datasets in order to validate whether we are able to define
subclasses of glioblastoma using just SAC genes. In the future, it
will be worth studying whether all three sets of predictors can be
combined into an even more powerful predictor, at least for grade
IV glioblastomas.
Our model of BUB1B RNA expression provided median
survival estimates very close to the observed median survival rate
for the WHO grades in leave-one-out cross validation. There are
inevitably some outliers in any model of clinical data (Figure 2)
because the models cannot take into account other important
factors such as differences in sample sources, treatments, genes in
other pathways, and other potential biological factors. This issue
can be addressed by using samples with more detailed follow-up
examinations and qPCR assays for more related genes. It is
notable how few outliers are seen even without this additional
information.
Why do SAC gene expression levels increase with increasing
grade in gliomas? The simplest explanation is that expression is
simply correlated with the rate of cell division, which is, in turn
correlated with survival time.
Another possibility is that increased SAC gene expression is a
homeostatic response to defects in other molecular components.
The mitotic spindle assembly checkpoint ensures that cells with
defective mitotic spindles or defective interaction between the
spindles and kinetochores do not initiate chromosomal segregation
during mitosis. The SAC can protect the cell from chromosome
mis-segregation and aneuploidy during cell division [59,60].
Increased chromosomal instability is a major driving force for
tumor development and progression [28,54,61]. In general, tumor
cells become increasingly aneuploid with tumor progression
[62,63]. Increased SAC gene expression is correlated with
aneuploidy in breast cancer [45]. Previous studies have proven
that defects in the mitotic checkpoint might contribute to
tumorigenesis [59,64]. However, total loss of checkpoint gene
function can be catastrophic even for cancer cells [65], making the
SAC a potentially interesting target for therapy in brains, where
the side effect of inhibiting cell division may have little
consequence.
Another possible mechanism for the changes in expression we
observed would be mutations in one or more SAC gene. To date,
only one study has found such mutations; BUB1 mutation is
associated with lymph node metastasis and shorter relapse-free
survival after surgery in colorectal cancers [54]. In contrast, studies
have failed to find mutations in BUB1, BUB1B and BUB3 as a
significant causation of chromosomal instability in glioblastomas
[66]. Mutations were not found in mitotic checkpoint genes in
breast cancer [45], bladder cancer [67] or gastric cancer [68].
Thus, change in SAC gene expression could be due to lesion in
other genes that act to increase cell division. A search for
epigenetic changes in SAC genes may be fruitful.
Preliminary immunohistochemistry evidence indicates that the
proteins encoded by the SAC genes investigated here are also
induced in gliomas, with BUB1B again being the most significant
(Table 5). Thus immunohistochemistry might be useful as an
alternative to qPCR as a prognostic assay. Furthermore, the
spatial resolution of immunohistochemistry within cells or across a
tumor might identify tumors where only a portion is highly
Table 5. Wilcox rank sum test of proteins between normal samples and malignant glioma samples.
Proteins Normal samples Grade III+IV glioma samples p
Negative Weak Moderate Negative Weak Moderate Strong
BUB1 0 0 3 0 0 4 7 0.036*
BUB1B 0 3 0 0 0 10 2 0.001*
BUB3 0 0 3 0 0 4 7 0.036*
CDC20 3 0 0 4 1 6 0 0.041*
MAD1L1 0 0 3 0 2 4 6 0.193
MAD2L1 3 0 0 9 1 0 0 0.358
TTK 0 3 0 1 2 8 0 0.038*
*p,0.05. Examples of immunohistochemical stains are shown in Information S10.
doi:10.1371/journal.pone.0025631.t005
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compared to qPCR-based estimates from bulk samples.
A single marker such as BUB1B will not capture all the
variability in subtypes of glioma. Instead, such a gene may be
useful in combination with other markers. Over the past decade,
there has been an increasing use of molecular markers in the
assessment and management of glioma patients [69]. For example,
the methylation of MGMT has been shown to be useful as a
prognostic biomarker in some circumstances [70]; EGFR vIII
expression enables identification of a subgroup of tumors with
more aggressive behavior [71]; and IDH1/IDH2 mutations have
strong prognostic value in grade III astrocytomas and in
glioblastomas [72]. A recent study identified a classifier based on
the RNA levels of nine genes that has potential value for therapy
optimization in glioblastoma (grade IV), the most advanced form
of glioma [57]. Another report divided glioblastoma into different
subtypes using cluster analysis of microarray expression data from
the literature [58]. Such differentiation into subclasses could lead
to different therapy strategies [42] as well as better clinical trial
designs.
In conclusion, two SAC genes, BUB1 and TTK, showed
increased RNA expression compared to normal brain even in the
lowest grades of glioma, perhaps indicating their future utility for
differentiating among low grade gliomas. Another SAC gene,
BUB1B is highly correlated with survival time, outperforming
other markers, including grade and Ki-67 mRNA level. Measuring
the expression of BUB1B gene might be a useful addition to the
repertoire of clinicians for staging gliomas. This ability to use just
one or a small handful of genes to predict outcome could have an
impact on clinical trials where matching patients across treatment
arms more accurately would lead to a considerable increase in
power.
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